The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Open accessAbstract
SNF'ing out antitumor immunity: Immune checkpoint inhibitors induce durable tumor regressions in some, but not all, cancer patients. Understanding the mechanisms that determine tumor sensitivity to these drugs could potentially expand the number of patients who benefit (see the Perspective by Ghorani and Quezada). Pan et al. discovered that tumor cells in which a specific SWI/SNF chromatin remodeling complex had been experimentally inactivated were more sensitive to T cell–mediated killing. The cells were more responsive to interferon-γ, leading to increased secretion of cytokines that promote antitumor immunity. Miao et al. examined the genomic features of tumors from patients with metastatic renal cell carcinoma who had been treated with immune checkpoint inhibitors. Tumors harboring inactivating mutations in PBRM1 , which encodes a subunit of the same SWI/SNF complex, were more likely to respond to the drugs. Science , this issue p. 770 , p. 801 ; see also p. 745
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Pooled in vivo and in vitro CRISPR-Cas9 based screening have nominated several tumour intrinsic drivers of resistance to immunotherapy 4,8-11 , but therapeutic applications of these findings remain limited.”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“thus it is surprising that TBK1 has been nominated as a candidate immune evasion gene 4,9-11”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“CRISPR/Cas9 KO screens in murine models or engineered human cell lines testing tumor-T cell interactions identified putative novel mechanisms of immune evasion involving chromatin regulators10, TNFα signaling11, SOX412, PTPN213, and APLNR10, yet their clinical relevance is unclear.”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [12]
In the citing paper
“consistent with prior reports12, induction of CD49f, which encodes an integrin associated with epithelial-to-mesenchymal transition (EMT).”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [12]
In the citing paper
“In previous screens, antigen-specific T cells targeting model tumor associated antigen (TAA), such as OVA, gp100, and NY-ESO-1, were used (Manguso et al., 2017; Pan et al., 2018; Patel et al., 2017).”
From Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens (2018) · cites this paper as Pan et al., 2018
In the citing paper
“Several studies have demonstrated that mutations in genes involved in the SWI-SNF chromatin remodeling complex may sensitize human tumors to ICIs and that treatment with an epigenetic modulator can potentiate the ICI-mediated antitumor response through increased production of chemokines responsible for recruiting CD8 + T cells (104-107).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Self-citationTrapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 857
Multi-omic alterations of the SWI/SNF complex define a clinical subgroup in lung adenocarcinoma
Peinado, P., Andrades, Á., Cuadros, M., Rodríguez, M. I., Coira, I. F., García, D. J., Benitez‐Cantos, M. S., Cano, C., Zarzuela, E., Muñoz, J., et al. (2022) · Clinical Epigenetics · doi:10.1186/s13148-022-01261-3 · Cited by 6
Liu, Y., Lv, G., Bai, J., Song, L., Ding, E. C., Liu, L., Tian, Y., Chen, Q., Li, K., Liu, X., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09537-w · Cited by 6
Self-citationBreaking the mold: Overcoming resistance to immune checkpoint inhibitors
Zhao, M., Yan, C.-Y., Wei, Y.-N., & Zhao, X. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105720 · Cited by 7
Li, G., LI, F., Wei, N., & Qing, J. (2023) · Biocell · doi:10.32604/biocell.2023.029986 · Cited by 6
Lysine demethylase 5B (KDM5B): A key regulator of cancer drug resistance
Cao, Y., Wu, C., & Ma, L. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23587 · Cited by 6
BRD7 as key factor in PBAF complex assembly and CD8+ T cell differentiation
Huang, F. H., Lin, Y., Qiao, Y., Yuan, Y., Zhong, Z., Luo, B., Wu, Y., Liu, J., Chen, J., Zhang, W., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.171605 · Cited by 6
Renal cell carcinoma pathology in 2021: ‘new need for renal cancer immune profiling’
Sobottka, B., Lorch, A., Siliņa, K., van den Broek, M. F., & Moch, H. (2021) · Current Opinion in Urology · doi:10.1097/mou.0000000000000864 · Cited by 6
Nong, J., Gu, Y., Yao, S., & Zhang, Y. (2021) · Medicine · doi:10.1097/md.0000000000026650 · Cited by 6
Wang, X., Jin, J., Yan, H., Liu, J., Huang, S., Bai, H., Guo, M., Cheng, X., Deng, T., Ba, Y., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ado4370 · Cited by 7
Lee, S., Yun, J. S., Kim, Y. J., Jeong, S., Noh, J. E., Kim, H.-O., Cho, H.-J., Park, C., Oh, I., & Cho, J.-H. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01448-7 · Cited by 8
Liu, S., Yuan, Y., He, J., Zhou, Y., Wang, Y., Ye, X., Wang, J., & Zhang, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1666121 · Cited by 6
Yang, B., Chen, S., Wang, Y., Wang, H., Deng, J., Liu, Y., Ran, J., Deng, Y., Li, T., Zhang, X., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07409-y · Cited by 5
CRISPR screens define unified hallmarks of cancer cell-autonomous immune evasion
Huber, A., Djajawi, T. M., Rivera, S., Vervoort, S. J., & Kearney, C. J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116738 · Cited by 5
Miglioli, C., Bakalli, G., Orso, S., Karemera, M., Molinari, R., Guerrier, S., & Mili, N. (2022) · Scientific Reports · doi:10.1038/s41598-022-08737-5 · Cited by 5
The perspective of targeting cancer cell metabolism: combination therapy approaches
Karimpur-zahmatkesh, A., & Khalaj‐Kondori, M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10472-9 · Cited by 5
Large-scale compound screens and pharmacogenomic interactions in cancer
McDermott, U. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.02.002 · Cited by 5
Zhou, Z., Huang, D., Yang, S., Liang, J., Wang, X., & Rao, Q. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610479 · Cited by 5
Single-cell CRISPR immune screens reveal immunological roles of tumor intrinsic factors
Hou, J., Liang, S., Xu, C., Wei, Y., Wang, Y., Tan, Y., Sahni, N., McGrail, D. J., Bernatchez, C., Davies, M. A., et al. (2022) · NAR Cancer · doi:10.1093/narcan/zcac038 · Cited by 7
Wangmu, T., Li, C., Han, G., & Yi, P. (2025) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000070 · Cited by 5
Genetic Screening for Novel Regulators of Immune Checkpoint Molecules
Arens, R., & Scheeren, F. A. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.005 · Cited by 6
SWI/SNF chromatin remodelers in prostate cancer progression
Ordonez‐Rubiano, S. C., Strohmier, B. P., Sood, S., & Dykhuizen, E. C. (2024) · Frontiers in Epigenetics and Epigenomics · doi:10.3389/freae.2023.1337345 · Cited by 5
Functional-genetic approaches to understanding drug response and resistance
Hinterndorfer, M., & Zuber, J. A. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.03.003 · Cited by 5
Improving Cancer Immunotherapy with CRISPR‐Based Technology
Li, Z., & Teng, F. (2020) · Advanced Biosystems · doi:10.1002/adbi.201900253 · Cited by 6
Simonaggio, A., Epaillard, N., Elaidi, R., Sun, C., Moreira, M., Oudard, S. M., & Vano, Y. A. (2020) · Bulletin du Cancer · doi:10.1016/s0007-4551(20)30275-7 · Cited by 5
Reva, B. A., Omelchenko, T., Calinawan, A. P., Nair, S. S., Schadt, E. E., & Tewari, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.19.345629 · Cited by 5
Brodeur, M. N., Dopeso, H., Zhu, Y., Longhini, A. L. F., Gazzo, A. M., Sun, S., Koche, R. P., Qu, R., Hamard, P.-J., Bykov, Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.08.552544 · Cited by 5
Zhu, L., Liu, Q., Zhao, C., Zhu, M., Yang, X., & Yang, J. (2025) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2024.2425170 · Cited by 4
Beyond the Tissue: Unlocking NSCLC Treatment Potential Through Liquid Biopsy
Kontić, M., Stjepanović, M., & Marković, F. (2025) · Genes · doi:10.3390/genes16080954 · Cited by 4
Gan, Y., Hu, Q., Hu, F., & Wu, S. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06284-w · Cited by 4
Hoch, C. C., Knoedler, L., Knoedler, S. A., Dezfouli, A. B., Schmidl, B., Trill, A., Douglas, J. E., Adappa, N. D., Stögbauer, F., & Wollenberg, B. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01506-9 · Cited by 4
Xiong, S., Zhou, J., & Chng, W. J. (2025) · Blood · doi:10.1182/blood.2025028403 · Cited by 4
Takaoka, H., Terai, H., Nakamura, K., Mizuno, T., Kawano, R., Emoto, K., Kurebayashi, Y., Takada, N., Hamabe, K., Horie, K., et al. (2025) · Cancer Science · doi:10.1111/cas.70168 · Cited by 4
Liu, S., Li, Q., Cao, M., Zhao, Z. B., Liu, C., Zhen, Z., Ren, J., Liu, C., Ruan, D., Zhang, L., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.11.022 · Cited by 4
Self-citationRNF31 promotes tumorigenesis via inhibiting RIPK1 kinase-dependent apoptosis
Zhang, J., Tu, H., Zheng, Z., Zhao, X., & Lin, X. (2023) · Oncogene · doi:10.1038/s41388-023-02669-8 · Cited by 5
Yin, C., Liu, Z.-J., He, C., & Yu, H.-X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1399868 · Cited by 4
The role of the polybromo-associated BAF complex in development
Park, J., & Kirkland, J. G. (2024) · Biochemistry and Cell Biology · doi:10.1139/bcb-2024-0224 · Cited by 4
Du, Y., Yang, Y., Zheng, B., Zhang, Q., Zhou, S., & Zhao, L. (2025) · Oncogene · doi:10.1038/s41388-025-03273-8 · Cited by 4
Ishihara, H., Kondo, T., Takagi, T., Tachibana, H., Fukuda, H., Yoshida, K., Iizuka, J., Kobayashi, H., & Tanabe, K. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0591-0 · Cited by 4
The future of immune checkpoint combinations with tumor-targeted small molecule drugs
Sceneay, J., & Sinclair, C. (2021) · Emerging Topics in Life Sciences · doi:10.1042/etls20210064 · Cited by 4
Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens
Yim, S., Hwang, W., Han, N., & Lee, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884561 · Cited by 4
The cancer epigenome: Non‐cell autonomous player in tumor immunity
Kato, S., Maeda, Y., Sugiyama, D., Watanabe, K., Nishikawa, H., & Hinohara, K. (2022) · Cancer Science · doi:10.1111/cas.15681 · Cited by 3
Wang, B., Deng, Y., Xu, Q., Gao, J., Shen, H., He, X., Ding, Q., Wang, F., & Guo, H. (2023) · Clinical Radiology · doi:10.1016/j.crad.2023.01.003 · Cited by 4
Exploring the immunological role and prognostic potential of PPM1M in pan-cancer
Zeng, R., Wang, L., Zhang, Y., Yang, Y., Yang, J., & Qin, Y. (2023) · Medicine · doi:10.1097/md.0000000000032758 · Cited by 3
Chen, J., Wang, Z., Zhu, Q., Ren, S., Xu, Y., Wang, G., & Zhou, L. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101918 · Cited by 4
Hou, Q., & Xu, H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_7 · Cited by 4
Kriplani, P. (2022) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892817666220804142633 · Cited by 4
The CRISPR System and Cancer Immunotherapy Biomarkers
Balan, V., & Wang, J. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_14 · Cited by 4
Xu, X. J., Li, J., Zou, J., Feng, X., Zhang, C., Zheng, R., Duanmu, W., Saha-Mandal, A., Ming, Z., & Wang, E. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/471912 · Cited by 4
Loss of Ubiquitin Ligase STUB1 Amplifies IFNγ-R1/JAK1 Signaling and Sensitizes Tumors to IFNγPreprint
Apriamashvili, G., Vredevoogd, D. W., Krijgsman, O., Bleijerveld, O. B., Ligtenberg, M. A., de Bruijn, B., Boshuizen, J., Altimari, D. M. D., Visser, N. L., Londino, J. D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.07.191650 · Cited by 4
Base editing screens map mutations affecting IFNγ signalling in cancerPreprint
Coelho, M. A., Karakoç, E., Bhosle, S. G., Gonçalves, E., Burgold, T., Cooper, S., Cattaneo, C. M., Veninga, V., Consonni, S., Dinçer, C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.29.486051 · Cited by 4
Li, Y., Yang, X., Zhu, W., Xu, Y., Ma, J., He, C., & Wang, F. (2022) · Research Square · doi:10.21203/rs.3.rs-1724646/v1 · Cited by 4
Tumuluru, S., Godfrey, J. K., Cooper, A. B., Yu, J., Chen, X., MacNabb, B. W., Venkataraman, G., Zha, Y., Pelzer, B. W., Song, J. Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.17.576100 · Cited by 4
Guo, J., Sun, D., Zhang, J., Guo, J., Wu, Z., Chen, Y., Xu, Y., Zhou, D., Cui, Y., Mo, Q., et al. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.10.020 · Cited by 3
Ye, C., Chen, X., Chen, Z., Liu, S., Kong, R., Lin, W., Zhu, M., Sun, X., & Xu, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1604394 · Cited by 4
Guo, Z., Li, X., Huang, L., Yan, Y., Gao, M., & Huang, J. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01706-x · Cited by 4
Huska, J. D., Doyle, K. J., Purkal, J. J., Hrusch, C. L., Duggan, R., Boghaert, E. R., Souers, A. J., Phillips, D. C., & Tahir, S. K. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08013-0 · Cited by 3
Chromatin remodeling complexes: architects influencing breast cancer progression
Giovani, O., Eckersley, G. S., Jones, H. R., & Nagarajan, S. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1690350 · Cited by 3
Prognostic Implications of SMARCA4 , ARID1A , and Other BAF Mutations in Non‐Small Cell Lung Cancer
Khalil, A., Collins, M. P., & Quintás‐Cardama, A. (2025) · Cancer Medicine · doi:10.1002/cam4.71442 · Cited by 3
Akana, R. V., Yoe, J., Laveroni, O., Sun, C., Kim, Y.-M., & Jerby‐Arnon, L. (2026) · Nature Genetics · doi:10.1038/s41588-026-02561-7 · Cited by 3
Nishida, N. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0071 · Cited by 3
Gudapati, P., & Abouamara, M. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-248156 · Cited by 3
A Review on CRISPR/Cas9 as a Novel Technique for Cancer Therapy
Saleem, A. A., & Al-Kelaby, K. K. A. (2022) · Cellular Therapy and Transplantation · doi:10.18620/ctt-1866-8836-2022-11-3-4-10-24 · Cited by 3
Meng, Z., Zhu, L., Liu, W., Yang, W., & Wang, Y. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285832 · Cited by 3
Hu, S., Duan, H., Lu, Y., & Huang, S. (2023) · Discover Oncology · doi:10.1007/s12672-023-00806-z · Cited by 3
Zhang, D., Wan, C., Chen, C., Li, Q., Mengke, L., Dou, M., Jiawei, Y., Longxi, Q., Liu, H., Liu, J., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-11949-9 · Cited by 3
Koebner phenomenon of vitiligo associated with Coffin-Siris syndrome
Hida, T., Ishikawa, A., Mizukami, M., & Uhara, H. (2020) · European Journal of Dermatology · doi:10.1684/ejd.2020.3778 · Cited by 3
CRISPR technology for immuno-oncology applications
Wang, J., Balan, V., & Marincola, F. M. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.05.018 · Cited by 3
[Development and applications of CRISPR/Cas9 library screening technology in cancer research].
Lei, T., Xiao, B., He, Y., Qu, J. T., Sun, Z., & Li, L. (2019) · Europe PMC (PubMed Central) · doi:10.12122/j.issn.1673-4254.2019.11.18 · Cited by 3
Jiang, X., Asad, M., Li, L., Sun, Z., Milanese, J., Liao, B., & Wang, E. (2020) · Quantitative Biology · doi:10.1007/s40484-020-0212-7 · Cited by 3
Ge, Y., Wang, Z., Li, H., Liu, Y., & Wei, P. (2022) · PubMed Central · Cited by 3
BAP1 Loss Predicts Therapeutic Vulnerability in Malignant Peritoneal MesotheliomaPreprint
Shrestha, R., Nabavi, N., Lin, Y.-Y., Mo, F., Anderson, S., Volik, S., Adomat, H. H., Lin, D., Xue, H., Dong, X., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/243477 · Cited by 3
Benham-Pyle, B. W., Brewster, C. E., Kent, A. M., Mann, F. G., Chen, S., Scott, A. R., Box, A., & Alvarado, A. S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.04.132753 · Cited by 3
Cancer-specific associations of driver genes with immunotherapy outcomePreprint
Jun, T. W., Qing, T., Dong, G., Signaevsky, M., Hopkins, J. F., Frampton, G. M., Albacker, L. A., Cordon‐Cardo, C., Samstein, R. M., Pusztai, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.16.155895 · Cited by 3
Demidova, E. V., Ghatalia, P., & Arora, S. (2021) · European Urology · doi:10.1016/j.eururo.2021.10.028 · Cited by 3
Integrative multi-omics analysis reveals molecular subtypes and tumor evolution of synovial sarcomaPreprint
Chen, Y., Su, Y., Leo, I. R., Siavelis, I., Zeng, J., Cao, X., Tsagkozis, P., Hesla, A. C., Papakonstantinou, A., Liu, X., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.09.490894 · Cited by 3
Self-citationInhibiting tumor cell-intrinsic UBA6 by inosine augments tumor immunogenicity
He, B., Zhang, L., Jiang, L., Yu, L., Li, Q., Tian, X., He, J.-Q., Zeng, L., Yang, Y., Wang, C., et al. (2021) · doi:10.21203/rs.3.rs-620390/v1 · Cited by 82
Tumor Cell–Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy
Li, S., Shapiro, J. W., Shah, H., Higgs, E. F., Xie, L., Li, Y., Zha, Y., Trujillo, J., Cabanov, A., Jones, T. A., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0519 · Cited by 2
Zhang, F., Liu, R., & Wu, L. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108578 · Cited by 2
Lasaviciute, G., Tariq, K., Sugathan, A., Quin, J. E., Polenkowski, M., Bujila, I., Skorokhod, O. A., Troye‐Blomberg, M., Sverremark‐Ekström, E., & Farrants, A. Ö. (2025) · iScience · doi:10.1016/j.isci.2025.113046 · Cited by 5
Comprehensive analysis of BRCA1/2 mutations, “BRCAness” and PARP inhibitors in melanoma
Stylianakis, D., Stylianakis, I., Benjamin, H. A., Martella, S., Tziotis, A., Pellegrino, B., Silva, P. D., Giannakis, M., Perrone, F., Lambertini, M., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104962 · Cited by 2
Huang, J., Xie, R., Li, J., Yao, X., Gu, Y., Yan, W., Dou, C., He, Y., Luo, P., Gao, Y., et al. (2025) · Medicine · doi:10.1097/md.0000000000045038 · Cited by 2
A TAK1 cytokine toxicity checkpoint controls anti-cancer immunity
Djajawi, T. M., Huber, A., Rivera, S., Srivaths, A., Salehi, M., Gunay, G., Gerak, C., Neil, L., Ozaydin, O., Voulgaris, O., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116665 · Cited by 3
Tang, W., Wang, L., Li, X., Yan, X., Guo, Q., Wu, Q., Cui, C., Liu, B., Zhang, J., Zhang, L., et al. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.12.007 · Cited by 2
Zhang, F., Dong, C., Chow, R. D.-W., Xin, S., He, E., Feng, Y., Zhu, L., Mirza, D., Tian, X., Yang, L., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0545 · Cited by 2
The SWI/SNF complex in tumor metabolism: Mechanisms and therapeutic implications
Pan, X.-H., Wang, J., Su, J., Zhao, R., & Gao, Y.-F. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.111342 · Cited by 3
Epigenetic therapy combined with radiotherapy reshapes tumor immune response
Wang, J., Xu, J., Ma, X., Wang, Q., Liu, Z., Zhang, X., Wei, Y., Wang, S., Liang, C., & Zhai, P. (2026) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2026.105040 · Cited by 2
PBRM1 presents a potential prognostic marker and therapeutic target in duodenal papillary carcinoma
He, X., Xu, J., Niu, N., Xu, G., Zhu, H., Liu, Z., Mou, Y., Qian, Z., Wang, H., Hu, J., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1062 · Cited by 2
Heterogeneity in functional genetic screens: friend or foe?
Vredevoogd, D. W., & Peeper, D. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1162706 · Cited by 3
Chen, X., Wu, J., Pang, G., Wei, S., & Wang, P. (2023) · Cureus · doi:10.7759/cureus.42934 · Cited by 2
Muto, S., Ozaki, Y., Yamaguchi, H., Watanabe, M., Okabe, N., Matsumura, Y., Hamada, K., & Suzuki, H. Y. (2025) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10409 · Cited by 3
Muscleblind-like proteins are novel modulators of the tumor-immune microenvironment
Gabel, A. M., Crosse, E. I., Belleville, A. E., Hogg, S. J., McKellar, S. A., Abdel-Wahab, O. I., Thomas, J. D., & Bradley, R. K. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321148 · Cited by 2
Cancer Resistance to Immunotherapy
Khoury, R., Shayya, A., Orm, C. B., Deen, O. Z., & Ghanem, H. (2025) · Immuno · doi:10.3390/immuno5030032 · Cited by 2
Chang, Q., Fan, L., Li, M., & Liu, L. (2023) · Medicine · doi:10.1097/md.0000000000033059 · Cited by 2
Yang, B., Rong, X., Jiang, C., Long, M., Liu, A., & Chen, Q. (2023) · Aging · doi:10.18632/aging.204693 · Cited by 2
Opposing immune and genetic forces shape oncogenic programs in synovial sarcomaPreprint
Jerby‐Arnon, L., Neftel, C., Shore, M. E., McBride, M. J., Haas, B. J., Izar, B., Weissman, H. R., Volorio, A., Boulay, G., Cironi, L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/724302 · Cited by 2
Chen, Z., Arai, E., Khan, O., Zhang, Z., Ngiow, S. F., He, Y. M., Huang, H., Manne, S., Cao, Z., Baxter, A. E., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.20.087379 · Cited by 2
Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killingPreprint
Frey, N., Tortola, L., Egli, D., Janjuha, S., Marquart, K. F., Rothgangl, T., Ampenberger, F., Köpf, M., & Schwank, G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.29.453937 · Cited by 2
Ichikawa, K., Adam, A., Wu, H., Lahr, D. L., Xu, L., Antonakos, B., Johannessen, L. H., Bellon, S. F., Kruger, R. G., Centore, R. C., et al. (2022) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2022-sitc2022.0888 · Cited by 2
Lee, C., DiNatale, R. G., Chowell, D., Krishna, C., Makarov, V., Valero, C., Vuong, L. H., Lee, M., Weiss, K. L., Hoen, D., et al. (2023) · doi:10.1158/1541-7786.c.6545243 · Cited by 2
Khalil, M. I., Wang, J., Yang, C., Vu, L., Yin, C., Chadha, S., Nabors, H., Vocelle, D. B., May, D. G., Chrisopolus, R. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.29.626106 · Cited by 2
Metadata
- Authors
- Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., Long, H. W., Yuan, G.-C., Doench, J., Brown, M., Liu, X. S., & Wucherpfennig, K. W.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Astellas Pharma (Japan) (JP)
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Broad Institute (US)
- Harvard University (US)
- Corresponding author
- Pan, Deng
- Kobayashi, Aya
- Jiang, Peng
- Liu, X. Shirley
- Wucherpfennig, Kai W.
- ORCID
- Venue
- Science
- Published
- 2018-02-16
- Volume
- 359
- Issue
- 6377
- Pages
- 770-775
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5953516
- OpenAlex
- W2782124401
- Cited by
- 852
- References
- 51
- Citations by year
- 2026: 39 · 2025: 96 · 2024: 92 · 2023: 107 · 2022: 123 · 2021: 117 · 2020: 143 · 2019: 86 · 2018: 47
- FWCI
- 36.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (R01CA173750)
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- SWI/SNF complex, PBRM1, immune checkpoint inhibitors, T cell-mediated killing, antitumor immunity, interferon-gamma, renal cell carcinoma, chromatin regulation
- MeSH terms
- CRISPR-Associated Protein 9, Bromodomain Containing Proteins, Animals, Bacterial Proteins, Chromosomal Proteins, Non-Histone, Cytotoxicity, Immunologic, DNA-Binding Proteins, Endonucleases, Genetic Testing, Humans, Immunotherapy, Interferon-gamma, Melanoma, Experimental, Skin Neoplasms, T-Lymphocytes, Cytotoxic, Transcription Factors, HMGB Proteins, Cell Line, Tumor, Mice, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
